The ？mportance Of Genetic Polymorphism Of CYP 2D6 ？n Breast Cancer Patients Treated With Tamoxifen

Abstract Tamoxifen constitutes the cornerstone of the treatment of estrogen receptor positi-ve breast cancer patients. Tamoxifen effectiveness is dependent on the biotransformation. Metabolism is predominantly carried out by the CYP 2D6 isoform and tamoksifen is converted to its active metabolit endoxifen. Both genetic and environmental factors can modify the CYP 2D6 enzyme activity, hence it can directly affect the concentrations of active metabolite of tamoxifen. In a number of studies it has shown CYP 2D6genetic variants may affect the clinical outcomes of patients treated with adjuvant tamoxifen. People in private therapy practice, the link between the CYP 2D6 genotype andthe clinical response of TAM treatment being studied intensively, especially in breast cancer patients. In this review, we tried to summarize themolecular dynamics of CYP 2D6 genetic polymorphism which is associated with tamoxifen treatment response andthe importance of the clinic. We believe this information willshed light on the other studies